The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Antibody Comparison, 2011Antibody Testing in Postmortem Human Brain
Objective/Rationale:
Mutations in the gene for LRRK2 are the most common genetic cause for Parkinson’s disease (PD) and therefore the LRRK2 protein appears to be important for normal brain function... -
Research Grant, 2011LRRK2 Antibody Comparison 2011
Objective/Rationale:
LRRK2 (Leucine-Rich Repeat Kinase 2) is a protein thought to be involved in regulating signaling pathways in cells. Mutations in the gene for LRRK2 are associated with some... -
Target Validation, 2011Role of PARK18 in Parkinson's Disease
Objective/Rationale:
PARK18 is a genetic marker that was recently found to be associated with susceptibility to Parkinson’s disease (PD). The marker is encoded within the HLA-DRA gene, a gene that... -
MJFF Research Grant, 2011fMRI of First Degree Relatives of LRRK2 Positive PD Patients
Objective/Rationale:
First, to study the effect of the presence of the LRRK2 G2019S mutation on brain activation patterns in Parkinson’s disease (PD) patients who recently converted into a diseased...
-
Repositioning Drugs for PD, 2011Fasudil as a Novel Therapeutic for the Treatment of Parkinson's Disease
Objective/Rationale:
The therapeutic drug we will repurpose for Parkinson’s disease (PD) is fasudil, a kinase inhibitor with an impressive safety profile in humans. The target of fasudil is highly... -
Repositioning Drugs for PD, 2011DPP-4 Inhibitors for the Treatment of Parkinson's Disease
Objective/Rationale:
This is a collaborative research project between three organizations, NIDA, NIA and Pfizer, focused towards characterizing whether gliptins, a well-tolerated drug class effective...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.